Cancer-control outcomes of Radium-223-pretreated lutetium- 177-PSMA radioligand vs. Radium- 223-naïve mCRPC patients
Purpose Radium- 223 and Lutetium- 177 prostate-specific membrane antigen radioligand therapy (Lu- 177-PSMA) are approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Data on cancer-control outcomes of sequential therapy of Lu- 177-PSMA after radium- 223...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
07 April 2025
|
| In: |
European journal of nuclear medicine and molecular imaging
Year: 2025, Jahrgang: 52, Heft: 11, Pages: 4025-4032 |
| ISSN: | 1619-7089 |
| DOI: | 10.1007/s00259-025-07256-5 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00259-025-07256-5 Verlag, kostenfrei, Volltext: http://link.springer.com/article/10.1007/s00259-025-07256-5 
|
| Verfasserangaben: | Mike Wenzel, Lena Theissen, Daniel Groener, Maximilian Kriegmair, Markus Graefen, Tobias Maurer, Georg Salomon, Benedikt Hoeh, Carolin Siech, Severine Banek, Felix K.H. Chun, Philipp Mandel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1929414099 | ||
| 003 | DE-627 | ||
| 005 | 20251208235614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250701s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00259-025-07256-5 |2 doi | |
| 035 | |a (DE-627)1929414099 | ||
| 035 | |a (DE-599)KXP1929414099 | ||
| 035 | |a (OCoLC)1559701177 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wenzel, Mike |d 1991- |e VerfasserIn |0 (DE-588)1173350659 |0 (DE-627)1042480494 |0 (DE-576)515171514 |4 aut | |
| 245 | 1 | 0 | |a Cancer-control outcomes of Radium-223-pretreated lutetium- 177-PSMA radioligand vs. Radium- 223-naïve mCRPC patients |c Mike Wenzel, Lena Theissen, Daniel Groener, Maximilian Kriegmair, Markus Graefen, Tobias Maurer, Georg Salomon, Benedikt Hoeh, Carolin Siech, Severine Banek, Felix K.H. Chun, Philipp Mandel |
| 246 | 3 | 3 | |a Cancer-control outcomes of Radium-223-pretreated lutetium- 177-PSMA radioligand versus Radium- 223-naïve mCRPC patients |
| 264 | 1 | |c 07 April 2025 | |
| 300 | |b Diagramme | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 01.07.2025 | ||
| 520 | |a Purpose Radium- 223 and Lutetium- 177 prostate-specific membrane antigen radioligand therapy (Lu- 177-PSMA) are approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Data on cancer-control outcomes of sequential therapy of Lu- 177-PSMA after radium- 223 are rare. Methods Using the Frankfurt Metastatic Cancer database of the Prostate (FRAMCAP) database, we analyzed progression-free (PFS) and overall (OS) survival of patients after radium- 223 pretreatment vs. radium- 223-naïve controls undergoing Lu- 177-PSMA radioligand within 1 st- 7 th line mCRPC treatment. Results Of 329 Lu- 177-PSMA mCRPC patients 19% were radium- 223 pretreated, while 81% radium- 223-naïve. The median number of administered mCRPC systemic treatment administrations were significantly higher for radium- 223 pretreated patients (4 vs. 3, p < 0.01). No difference in further baseline or cancer characteristics were observed, similar to PSA response under Lu- 177-PSMA treatment. In PFS analyses, no significant difference between radium- 223 pretreated vs. radium- 223-naïve Lu- 177-PSMA mCRPC patients were observed, with median PFS of 16 vs. 12 months (hazard ratio [HR]: 0.73, confidence interval [CI]: 0.52-1.02, p = 0.063). In OS analysis, also no significant differences were observed with median OS of 18 vs. 15 months for radium- 223 pretreated vs. radium- 223-naïve Lu- 177-PSMA mCRPC patients (HR: 0.99, CI: 0.71-1.37, p > 0.9). Finally, after additional multivariable adjustment, no differences in PFS and OS outcomes between both groups were observed. Conclusion Sequential treatment with radium- 223 prior to Lu- 177-PSMA does not affect PFS or OS outcomes in mCRPC patients. Therefore, this real-world cohort suggests that both radiopharmaceuticals can be administered within mCRPC treatment algorithm. | ||
| 700 | 1 | |a Theissen, Lena |e VerfasserIn |4 aut | |
| 700 | 1 | |a Groener, Daniel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kriegmair, Maximilian |d 1987- |e VerfasserIn |0 (DE-588)1049742745 |0 (DE-627)782573347 |0 (DE-576)403726840 |4 aut | |
| 700 | 1 | |a Graefen, Markus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Maurer, Tobias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Salomon, Georg |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hoeh, Benedikt |e VerfasserIn |4 aut | |
| 700 | 1 | |a Siech, Carolin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Banek, Severine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chun, Felix K. H. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mandel, Philipp |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of nuclear medicine and molecular imaging |d Heidelberg [u.a.] : Springer-Verl., 2002 |g 52(2025), 11, Seite 4025-4032 |h Online-Ressource |w (DE-627)359787258 |w (DE-600)2098375-X |w (DE-576)110279549 |x 1619-7089 |7 nnas |a Cancer-control outcomes of Radium-223-pretreated lutetium- 177-PSMA radioligand vs. Radium- 223-naïve mCRPC patients |
| 773 | 1 | 8 | |g volume:52 |g year:2025 |g number:11 |g pages:4025-4032 |a Cancer-control outcomes of Radium-223-pretreated lutetium- 177-PSMA radioligand vs. Radium- 223-naïve mCRPC patients |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00259-025-07256-5 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u http://link.springer.com/article/10.1007/s00259-025-07256-5 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20250701 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1049742745 |a Kriegmair, Maximilian |m 1049742745:Kriegmair, Maximilian |d 60000 |d 63100 |e 60000PK1049742745 |e 63100PK1049742745 |k 0/60000/ |k 1/60000/63100/ |p 4 | ||
| 999 | |a KXP-PPN1929414099 |e 474095494X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Cancer-control outcomes of Radium-223-pretreated lutetium- 177-PSMA radioligand vs. Radium- 223-naïve mCRPC patients","title":"Cancer-control outcomes of Radium-223-pretreated lutetium- 177-PSMA radioligand vs. Radium- 223-naïve mCRPC patients"}],"language":["eng"],"name":{"displayForm":["Mike Wenzel, Lena Theissen, Daniel Groener, Maximilian Kriegmair, Markus Graefen, Tobias Maurer, Georg Salomon, Benedikt Hoeh, Carolin Siech, Severine Banek, Felix K.H. Chun, Philipp Mandel"]},"person":[{"family":"Wenzel","display":"Wenzel, Mike","given":"Mike","role":"aut"},{"family":"Theissen","display":"Theissen, Lena","given":"Lena","role":"aut"},{"family":"Groener","given":"Daniel","role":"aut","display":"Groener, Daniel"},{"family":"Kriegmair","display":"Kriegmair, Maximilian","role":"aut","given":"Maximilian"},{"given":"Markus","role":"aut","display":"Graefen, Markus","family":"Graefen"},{"family":"Maurer","given":"Tobias","role":"aut","display":"Maurer, Tobias"},{"display":"Salomon, Georg","role":"aut","given":"Georg","family":"Salomon"},{"display":"Hoeh, Benedikt","given":"Benedikt","role":"aut","family":"Hoeh"},{"family":"Siech","role":"aut","given":"Carolin","display":"Siech, Carolin"},{"display":"Banek, Severine","given":"Severine","role":"aut","family":"Banek"},{"family":"Chun","display":"Chun, Felix K. H.","given":"Felix K. H.","role":"aut"},{"role":"aut","given":"Philipp","display":"Mandel, Philipp","family":"Mandel"}],"titleAlt":[{"title":"Cancer-control outcomes of Radium-223-pretreated lutetium- 177-PSMA radioligand versus Radium- 223-naïve mCRPC patients"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"07 April 2025","dateIssuedKey":"2025"}],"recId":"1929414099","id":{"eki":["1929414099"],"doi":["10.1007/s00259-025-07256-5"]},"physDesc":[{"noteIll":"Diagramme"}],"relHost":[{"part":{"issue":"11","volume":"52","year":"2025","text":"52(2025), 11, Seite 4025-4032","pages":"4025-4032"},"language":["eng"],"title":[{"subtitle":"official journal of the European Association of Nuclear Medicine (EANM)","title":"European journal of nuclear medicine and molecular imaging","title_sort":"European journal of nuclear medicine and molecular imaging"}],"pubHistory":["29.2002 -"],"note":["Gesehen am 13.02.2023","Ungezählte Beil.: Supplement"],"disp":"Cancer-control outcomes of Radium-223-pretreated lutetium- 177-PSMA radioligand vs. Radium- 223-naïve mCRPC patientsEuropean journal of nuclear medicine and molecular imaging","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["359787258"],"issn":["1619-7089"],"zdb":["2098375-X"]},"origin":[{"dateIssuedKey":"2002","publisher":"Springer-Verl.","dateIssuedDisp":"2002-","publisherPlace":"Heidelberg [u.a.]"}],"recId":"359787258","type":{"bibl":"periodical","media":"Online-Ressource"}}],"note":["Gesehen am 01.07.2025"]} | ||
| SRT | |a WENZELMIKECANCERCONT0720 | ||